A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression

In a 6-week double-blind study, 220 patients with major depression (mostly outpatients) were randomly assigned to receive a fixed dose of brofaromine 150 mg daily ( n = 111) or placebo ( n = 109) after a 1-week single-blind placebo washout. Except for the HAM-D sleep items, brofaromine was superior...

Full description

Saved in:
Bibliographic Details
Published in:Journal of affective disorders 1994-10, Vol.32 (2), p.105-114
Main Authors: Chouinard, G., Saxena, B.M., Nair, N.P.V., Kutcher, S.P., Bakish, D., Bradwejn, J., Kennedy, S.H., Sharma, V., Remick, R.A., Kukha-Mohamad, S.A., Belanger, M.C., Snaith, J., Beauclair, L., H., Pohlmann, D'Souza, J.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Biological and medical sciences
Depressive Disorder - drug therapy
Depressive Disorder - psychology
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Humans
Male
Medical sciences
Middle Aged
Monoamine Oxidase Inhibitors - administration & dosage
Monoamine Oxidase Inhibitors - adverse effects
Neuropharmacology
Personality Inventory
Pharmacology. Drug treatments
Piperidines - administration & dosage
Piperidines - adverse effects
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a 6-week double-blind study, 220 patients with major depression (mostly outpatients) were randomly assigned to receive a fixed dose of brofaromine 150 mg daily ( n = 111) or placebo ( n = 109) after a 1-week single-blind placebo washout. Except for the HAM-D sleep items, brofaromine was superior to placebo on measures of depression as determined by the four methods of assessing drug efficacy: (1) psychiatric symptom rating (HAM-D 17-item less the three sleep items); (2) self-rating scale (Beck Depression Inventory); (3) Clinical Global Assessment of Efficacy; and (4) drop-out rate due to lack of efficacy. Most commonly reported adverse events with brofaromine were: headache, nausea, dizziness and sleep disturbance. Brofaromine was found to be an effective antidepressant, superior to placebo with a good tolerability profile.
ISSN:0165-0327
1573-2517
DOI:10.1016/0165-0327(94)90068-X